Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in Vigibase-Reference-Cited by-同舟云学术

Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in Vigibase

Published:2020-02-03 Issue:5 Volume:86 Page:991-998
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Perino Justine¹^ORCID,Mottal Nathan²,Bohbot Yohann³,Servant Vincent⁴,Berroneau Aude⁴,Poustis Pierre⁵,Fenaux Pierre⁶,Laribi Kamel⁷,Charbonnier Aude⁸,Bilion Emilien⁸,Calmettes Claire²,Bégaud Bernard⁹,Pigneux Arnaud²,Milpied Noël²,Miremont‐Salamé Ghada¹⁹,Théophile Hélène¹,Dimicoli‐Salazar Sophie²

Affiliation:

1. CHU de Bordeaux, Pôle de Santé PubliqueService de pharmacologie médicale, Centre Régional de pharmacovigilance de Bordeaux Bordeaux France

2. CHU de Bordeaux, Service d'Hématologie Clinique et Thérapie Cellulaire Bordeaux France

3. CHU d'Amiens, Pôle Cœur‐Thorax‐Vaisseaux, Département de Cardiologie Amiens Cedex France

4. Pharmacie à Usage Intérieur, CHU de Bordeaux Pessac France

5. Service des soins intensifs cardiologiques Haut‐Lévêque (intensive care unit) Pessac France

6. Service d'Hematologie Seniors, Hôpital Saint LouisAss Pub Hôp Paris and Paris 7 Université Paris France

7. Service d'Hematologie, Centre Hospitalier du Mans Le Mans France

8. Service d'Hematologie, Institut Paoli Calmettes Marseille France

9. Univ. Bordeaux, Inserm, Bordeaux Population Health Research Centre, team Pharmacoepidemiology Bordeaux France

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14211

Reference29 articles.

1. International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

2. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

3. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C

4. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

5. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating the performance of BN nanotubes as drug delivery systems for Azacitidine and Decitabine anti-cancer drugs: A theoretical study;Computational and Theoretical Chemistry;2024-01

2. Antimicrobial, antioxidant, and in silco studies of divalent metal complexes of novel aminopyrimidine Schiff base chelators;Journal of Molecular Structure;2023-11

3. Epigenetic modifier alpha-ketoglutarate modulates aberrant gene body methylation and hydroxymethylation marks in diabetic heart;Epigenetics & Chromatin;2023-04-27

4. Adverse Event Profile of Azacitidine: Analysis by Route of Administration Using Japanese Pharmacovigilance Database;Oncology;2023

5. Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents;Blood Advances;2022-09-12